問卷

TPIDB > Search Result

Search Result

篩選

List

11Cases

2020-05-12 - 2025-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting6Sites

Recruiting2Sites

2021-10-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-09-01 - 2025-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2021-05-20 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting1Sites

Terminated3Sites

2021-10-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2024-10-04 - 2027-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-08-19 - 2024-04-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2021-12-01 - 2022-12-01

Phase II

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 versus Placebo in Gout Patients
  • Condition/Disease

    Gout

  • Test Drug

    AR882

Participate Sites
5Sites

Recruiting5Sites

2015-10-01 - 2022-06-22

Phase III

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non–small-cell lung cancer
  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated7Sites

1 2